MedTrace Logo

Alfuzosin XL Lower Urinary Tract Symptoms Efficacy and Sexuality Study

NCT00575913 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 118

Last updated 2008-04-10

No results posted yet for this study

Summary

To assess, under daily practice conditions, the safety profile and the efficacy of a new formulation of alfuzosin administered once daily (Xatral XL) in patients with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH).

Conditions

  • Prostatic Diseases

Interventions

DRUG

Alfuzosin

Alfuzosin 10 mg One tablet per day after evening meal

Sponsors & Collaborators

Principal Investigators

  • Paibulsirijit Sompob · Sanofi

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-09-30
Completion
2005-03-31

Countries

  • Thailand

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00575913 on ClinicalTrials.gov